Skip to main content
. Author manuscript; available in PMC: 2016 Jan 13.
Published in final edited form as: Sci Signal. 2015 Jan 13;8(359):ra4. doi: 10.1126/scisignal.2005906

Figure 5. Predictive capacity of EGFR:GRB2 PLA for cetuximab response in PDX tumors.

Figure 5

(A) 2×2 contingency tables demonstrating EGFR:GRB2 PLA analytical performance to predict robust response to cetuximab (defined as >70% tumor reduction in treated compared to untreated mice). All cancers: P = 0.006; NSCLC only: P = 0.18, Two-tailed Fisher's exact test. (B) Graphs of the % of tumor inhibition in mice treated with cetuximab (50 mg/kg; day 0, 7, 14) compared to untreated mice and sacrificed on day 28. Bars are colored to reflect EGFR:GRB2 PLA score. Lines at 30% (representing 70% reduction in tumor size) demarcate the cutoff between responders (below) and non-responders (above). Drug resistance-associated mutations and molecular events are also annotated. K = KRAS mutant (G12×), B = BRAF mutant, N = NRAS mutant, M = phosphorylated Met, A = phosphorylated AKT, H = phosphorylated HER3.